unusually cautious<\/strong>, with companies running simultaneous deal processes, over-analyzing every aspect, and often walking away late in negotiations. \u201cIn the absence of competitive tension, why should anybody move fast?\u201d he asked.<\/p>\n\n\n\nValuation disconnects are the core issue<\/h4>\n\n\n\n
In a volatile market, stock prices can swing by 5% to 10% in a single week, making it nearly impossible to agree on a price. What looks like a reasonable premium on Monday could become untenable by Friday if the target\u2019s stock drops.<\/p>\n\n\n\n
This pricing friction is halting many deals in their tracks. \u201cWe\u2019ve seen deals fall apart, term sheets not get signed because they\u2019re so far apart on valuation,\u201d Merken said.<\/p>\n\n\n\n
Merck & Co. CEO Rob Davis echoed this during a recent earnings call: \u201cThere\u2019s a disconnect between the market realities sellers face and the value expectations they hold.\u201d<\/p>\n\n\n\n
Biotechs are losing leverage<\/h4>\n\n\n\n
A few years ago, small and mid-sized drug developers had ample access to venture capital and strong IPO markets. Today, with capital harder to come by and more dilutive than ever, large pharmaceutical firms hold the upper hand.<\/p>\n\n\n\n
Some are using that leverage to wait out cash-strapped biotechs, hoping desperation will push sellers to accept lower bids.<\/p>\n\n\n\n
\u201cIf I\u2019m the head of business development for a company,\u201d said Merken, \u201cI would rather kill a deal than take significant risk that could damage my career.\u201d<\/p>\n\n\n\n
Activity behind the scenes remains strong<\/h4>\n\n\n\n
Despite these headwinds, the pipeline for dealmaking isn\u2019t empty. Experts say the behind-the-scenes activity remains heathy, particularly in research collaborations and asset licensing.<\/p>\n\n\n\n
\u201cThere’s still lots of activity happening underneath the surface,\u201d Kingston noted. Lower-risk, partnership-based deals are now taking center stage \u2014 and Cable said his team handling collaborations is \u201cbusier than ever.\u201d<\/p>\n\n\n\n
Pharma buyers are also focused on \u201cderisked\u201d assets: therapies supported by solid clinical data with clear commercial upside. Unfortunately, such opportunities remain limited, which makes them fiercely competitive.<\/p>\n\n\n\n
Mid-sized deals are most likely to close<\/h4>\n\n\n\n
Deals in the $1 billion to $5 billion range appear to be the sweet spot for 2025<\/strong>, according to Davidson and others. That view gained credibility with Merck KGaA\u2019s $3.9 billion acquisition of cancer-focused SpringWorks Therapeutics in May, a deal carrying a 26% premium to its trailing average.<\/p>\n\n\n\nDeals exceeding $10 billion, however, are increasingly rare. \u201cThey\u2019re not impossible,\u201d said Davidson, \u201cbut they\u2019re certainly harder to justify in this environment.\u201d<\/p>\n\n\n\n
Unless political and economic clarity returns, many dealmakers will likely stay cautious. As BMO Capital\u2019s Evan Seigerman put it: \u201cIf I do it now or three months from now, nothing\u2019s really going to change.\u201d<\/p>\n\n\n\n
That delay could have long-term consequences for biotech investing. Much of the sector\u2019s appeal rests on the possibility of a lucrative pharma buyout. If that \u201ctakeout thesis\u201d weakens, investor enthusiasm may follow.<\/p>","protected":false},"excerpt":{"rendered":"
After a quiet period for biotech M&A, dealmakers started 2025 with renewed optimism. Many expected a rebound in billion-dollar transactions, bolstered by early momentum like Johnson & Johnson\u2019s $14.6 billion acquisition of neuroscience biotech Intra-Cellular Therapies, announced in January. Enthusiasm has since faded, with political instability and market swings cooling appetites and deepening the divide […]<\/p>\n","protected":false},"author":2,"featured_media":2638,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,32,55,58,57,7],"tags":[64,68,69,72,33,70,31],"class_list":["post-2637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-pharma-general","category-pharma-industry","category-latest-us-stock-market-news","category-pharma-investments","category-pharmaceutical","tag-biotech","tag-finance","tag-general","tag-industry","tag-investing","tag-north-america","tag-pharmaceutical"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=2637"}],"version-history":[{"count":2,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2637\/revisions"}],"predecessor-version":[{"id":2640,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/2637\/revisions\/2640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/2638"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=2637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=2637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=2637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}